Abstract
Introduction
The extracellular matrix (ECM) which defines the composition, architecture, signalling and biomechanics of the cellular microenvironment plays a dominant role in regulating the cellular processes, proliferation and differentiation of stem cells, and in maintaining the plasticity of stem cells [1] [2] [3] . It is still a challenge that the biological complexity of the native ECM is fully mimicked in the tissue-engineered constructs to which cells can attach, differentiate and function as a living tissue [4] .
Matrigel is one of the injectable matrix biopolymers. It is a basement membrane protein mixture secreted by a mouse sarcoma [5] . It contains ECM components such as laminin, collagen IV, entactin and hepran sulphate proteglycan [5] , as well as growth factors including basic fibroblast growth factor # These authors contributed equally to this work. [6] . The biologically active heterogeneous compositions in matrigel could influence cell gene expression [7] [8] [9] [10] [11] [12] , regulate complex cellular behaviour including attachment, proliferation and differentiation [13] [14] [15] [16] [17] , and promote angiogenesis both in vitro [18, 19] and in vivo [20] [21] [22] . [23] [24] [25] [26] [27] [28] . This evidence fuelled significant interest in the potential use of matrigel as a cytoprotective agent and a very effective tool for construction of bioactive scaffolds for tissue-engineering applications in the cardiovascular system [24, 26] -intracardiac injection of matrigel can also induce neovascularization after MI [29] . Furthermore, injectable matrigel offers a potentially less invasive and more effective tissue-engineering approach for myocardial reconstruction [30] , in comparison with external scaffold patches, which require surgically invasive procedures to be fixed onto the epicardial surface and have thickness restrictions due to the lack of a vascular bed [25] . The ability of injectable matrigel to deform with the dynamically loaded myocardial environment to align their matrix with the injured region may provide better incorporation of implanted cells to the host tissue [23] .
(bFGF), epidermal growth factor (EGF), insulin-like growth factor-1 (IGF-1), platelet-derived growth factor (PDGF), nerve growth factor (NGF), transforming growth factor (TGF-␤) and other growth factors which have not been fully identified chemically

Matrigel as engineered ECM is an emerging area of research in cardiac tissue engineering. It showed tremendous promise in the treatment of myocardial infarction (MI). Matrigel can provide the adequate natural ECMs serving as structural support for the cells; it also provides an appropriate environment with above mentioned growth factors for cell survival and function as well. When used in combination with cells such as embryonic stem cells, endothelial cells, cardiomyocytes and bone marrow-derived stem cells, matrigel may serve as cell delivery vehicles by providing a favourable matrix environment that confers cell viability, migration and proliferation
In order to fully exploit the potential application of matrigel in the cardiovascular system, it is helpful to understand the mechanisms involved in the matrigel-mediated neovascularization. Therefore, we evaluated the therapeutic efficacy of intracardiac matrigel injection in the infarcted heart. We found that intracardiac injection of matrigel could confer effective cardiac protection and recruit stem cells to the infarcted heart and promote cardiac regeneration after MI. Fig. 2D ).
Materials and methods
Experimental design
Results
Local matrigel delivery improves cardiac functions
Local matrigel injection promotes neoangiogenesis
Capillary density was analysed by immune staining with CD31 antibody (Fig. 3A-C (Fig. 3D ).
Local matrigel injection augments myocardial stem cell recruitment
To examine whether local matrigel delivery can home c-Kit ϩ and [34, 37] also found that matrigel can promote angiogenesis via recruitment of precursors from the surrounding tissues. C-kit is a receptor tyrosine kinase [39] , and expressed on cardiac progenitor cells [40, 41] , endothelial progenitor cells [42] and bone marrow derived cells, including haematopoietic stem/progenitor cells and mesenchymal stem cells [43] . Furthermore 
CD34 ϩ cells to infracted myocardial zone, c-Kit ϩ and CD34 ϩ cell number in the infarct zone of heart were assessed by immunostaining at 4 weeks after MI (Figs 4 and 5). There was a significant
Fig. 2 Effects of local matrigel injection on cardiac remodelling 4 weeks after MI. (A), (B) Representative heart cross sections stained with Sirius Red (red, fibrosis) and Fast Green FCF (green, myocyte) from rats. (C) Ratio of infarction size to entire heart is not significantly decreased in MI-M (n ϭ 10) compared with MI-PBS (n ϭ 10). (D) The infarct LWT is significantly higher in MI-M (n ϭ 10) compared with MI-PBS (n ϭ 10). *P Ͻ 0.01.
Fig. 1 Local matrigel injection improved cardiac functions 4 weeks after MI assessed by catherization. Left ventricular function (EF, dp/dt max and dp/dt min, n ϭ 11) is significantly improved in MI-
Fig. 3 Local matrigel injection induces neovascularization 4 weeks after MI. Endothelial CD31 were stained in the border of the infarct of hearts. Representative micrographs of the border of the infarct in the three groups of animals [(A) Sham, (B) MI-PBS, (C) MI-M, Blue, DAPI in nuclei, 400ϫ]. (D) Morphometric analysis of vessel density in the border
Stem cell microenvironment which is defined by various growth factors and ECM is a determined factor for stem cell local activity, such as adhesion, differentiation and proliferation
c-Kit ϩ cells (green) were identified in infarct border zone at 4 weeks after treatment. Red, TOPRO3 in nuclei. Yellow is shown after green [(A), sham, (B),
MI-PBS, (C-F), MI-M]. (D) The number of c-Kit
